type: misc

label: url

en: Treatment-induced and pre-existing anti-PEG antibodies: Prevalence, clinical implications, and future perspectives

en: Journal of Pharmaceutical Sciences

ja: Journal of Pharmaceutical Sciences


en: Polyethylene glycol (PEG): The nature, immunogenicity, and role in the hypersensitivity of PEGylated products

en: Journal of Controlled Release

ja: Journal of Controlled Release


en: The challenge to deliver oxaliplatin (l-OHP) to solid tumors: development of liposomal l-OHP formulations

en: Chemical & Pharmaceutical Bulletin

ja: Chemical & Pharmaceutical Bulletin


en: DDS抗がん剤の腫瘍内局在の解明と腫瘍微小環境改善による効果増強

ja: DDS抗がん剤の腫瘍内局在の解明と腫瘍微小環境改善による効果増強

en: Journal of the Pharmaceutical Society of Japan

ja: 薬学雑誌


en: An RNAi therapeutic, DFP-10825, for intraperitoneal and intrapleural malignant cancers

en: RNA interference (RNAi), a potent post-transcriptional gene-silencing action, has received considerable attentions as a novel therapeutic tool to treat intractable cancers. In recent days, we have developed a novel RNAi-based therapeutic formulation, DFP-10825, for the treatment of intractable advanced cancers developed in coelomic cavities. DFP-10825 was composed of chemically synthesized short hairpin RNA (shRNA) against thymidylate synthase (TS), a key enzyme for cancer proliferation, and cationic liposomes, and achieved high therapeutic effect on the mouse models of peritoneally disseminated gastric and ovarian cancers and malignant pleural mesothelioma without severe side effects by intracoelomic direct treatment. We further designed a freeze-dried DFP-10825 formulation for mass industrial production. DFP-10825 is undergoing in pre-clinical phase and goes to clinical trials. This review introduces a DFP-10825 formulation, a potent novel RNAi-based therapeutic maximizing the benefit of RNAi molecule (shRNA).

en: Advanced Drug Delivery Reviews

ja: Advanced Drug Delivery Reviews


en: 臨床応用可能な体腔内投与型RNAi 製剤(DFP-10825)の開発と難治性がんに対する治療

en: Medchem News

ja: Medchem News


en: リポソームDDS 製剤開発における免疫系の制御と動態解析の重要性

ja: リポソームDDS 製剤開発における免疫系の制御と動態解析の重要性

en: Oleoscience

ja: オレオサイエンス


en: ナノフィブリル化バクテリアセルロース(Fibnano)を用いた腹腔内投与型がん治療製剤への応用

en: Cellulose Communications

ja: Cellulose Communications


en: フルーツ由来新奇酢酸菌によるナノセルロースの合成とその応用

ja: フルーツ由来新奇酢酸菌によるナノセルロースの合成とその応用

en: Journal of The Brewing Society of Japan

ja: 日本醸造協会誌


en: Pharmaceutics of Nanoparticles

ja: Pharmaceutics of Nanoparticles

en: Nanomaterials in Pharmacology

ja: Nanomaterials in Pharmacology